Telomir Pharmaceuticals (TELO) Projected to Post Quarterly Earnings on Monday

Telomir Pharmaceuticals (NASDAQ:TELO) is expected to release its earnings data before the market opens on Monday, May 12th. Analysts expect Telomir Pharmaceuticals to post earnings of ($0.10) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). On average, analysts expect Telomir Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Telomir Pharmaceuticals Stock Up 3.2 %

Shares of TELO opened at $2.59 on Monday. The stock’s 50-day moving average price is $3.41 and its 200 day moving average price is $4.14. Telomir Pharmaceuticals has a 12-month low of $2.35 and a 12-month high of $8.40. The firm has a market capitalization of $77.09 million, a price-to-earnings ratio of -4.47 and a beta of 0.17.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A hedge fund recently raised its position in Telomir Pharmaceuticals stock. Bank of America Corp DE boosted its stake in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 283.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,713 shares of the company’s stock after buying an additional 10,880 shares during the quarter. Bank of America Corp DE’s holdings in Telomir Pharmaceuticals were worth $61,000 at the end of the most recent quarter.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. RODMAN&RENSHAW upgraded Telomir Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 20th. Rodman & Renshaw assumed coverage on shares of Telomir Pharmaceuticals in a report on Friday, February 21st. They set a “buy” rating and a $15.00 price objective for the company.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.